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ABSTRACT In this review, constituting the 1990 International Lecture of the Biophysical Society, research is described in two
areas in which molecular genetic techniques were used to dissect problems related to sarcoplasmic reticulum proteins: the
use of site-directed mutagenesis to gain insight into the mechanism of Ca2+ transport by the Ca2+-ATPase; and the use of
cloning and genetic linkage analysis to identify the Ca2+ release channel (RYR 1) gene as a candidate gene for the
predisposition to malignant hyperthermia, a neuromuscular disease of humans and domestic animals.
INTRODUCTION
The sarcoplasmic reticulum is an extensive muscle mem-
brane system surrounding each myofibril within muscle
cells. It lies at the junction between the transverse tubule,
the intracellular extension of the electrically excitable
sarcolemmal membrane, and the contractile apparatus of
the muscle cell, forming a part of the pathway of
excitation-contraction coupling. Depolarizing currents in
the transverse tubule culminate in a signal for Ca2+
release from the sarcoplasmic reticulum and Ca2+ re-
leased from the sarcoplasmic reticulum regulates muscle
contraction. The sarcoplasmic reticulum has two addi-
tional functions essential to excitation-contraction cou-
pling, Ca2+ reuptake to initiate muscle relaxation and
Ca2+ storage to maintain relaxed muscle in a quiescent
state. This concept was well understood in 1969, when I
began to work on the system, and was summarized in a
superb review by Dr. S. Ebashi and his colleagues in that
year (Ebashi et al., 1969).
My goal in studies of the sarcoplasmic reticulum, after
6 years of training with the pioneer of membrane protein
fractionation and isolation, Dr. David E. Green, was to
isolate and characterize the major proteins of the system
to understand how they related to Ca2+ transport, seques-
tration, and release. The protein of most immediate
interest was the Ca2+ transport ATPase that Dr. Ebashi
had identified earlier (Ebashi and Lipmann, 1962), but,
on the basis of farsighted advice from Dr. Green, I chose
to work on the system of membrane proteins rather than
confining my work to a single protein. Our work led to the
isolation and partial characterization of the Ca2+-
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ATPase (MacLennan, 1970; MacLennan et al., 1985),
calsequestrin (MacLennan and Wong, 1971; Fliegel et
al., 1987), a proteolipid and a high affinity Ca2' binding
protein (calreticulin) (MacLennan et al., 1972; Fliegel et
al., 1989), a 53,000 glycoprotein (Campbell and MacLen-
nan, 1981; Leberer et al., 1989a) a 160,000 glycoprotein
(sarcalumenin) (Leberer et al., 1989b) and a calmodulin-
dependent protein kinase (Campbell and MacLennan,
1982; Tuana and MacLennan, 1988). With the advent of
recombinant DNA technology in the early 1980s, Chris
Brandl, then a graduate student, and I began to clone
cDNAs encoding these proteins. Thus we were not in-
volved with the isolation and identification of the Ca2,
release channel protein, or ryanodine receptor, which was
so ably executed in the laboratories of Tony Caswell,
Sidney Fleischer, Gerhard Meissner, and Kevin Camp-
bell (Cadwell and Caswell, 1982; Kawamato et al., 1986;
Smith et al., 1985; Inui et al., 1987; Lai et al., 1987, 1988;
Campbell et al., 1987). We were, however, able to
contribute to knowledge of this protein through cloning of
cDNA encoding skeletal (Zorzato et al., 1990) and
cardiac (Otsu et al., 1990) muscle isoforms of the protein
and through identification of the ryanodine receptor gene
as a candidate gene for the predisposition to malignant
hyperthermia (MacLennan et al., 1990).
In this review I will describe aspects of our work on two
different problems relating to sarcoplasmic reticulum
structure and function. In the first section I will describe
our use of cloning, expression, and site-directed mutagen-
esis to gain insight into the mechanism of Ca2+ transport
by the Ca2+-ATPase. In the second, I will describe our use
of cloning and genetic analysis to gain insight into the
structure, function, and involvement in disease of the
Ca2' release channel.
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THE Ca2+-ATPASE
Structure
The Ca2+ ATPase is comprised of cytoplasmic headpiece
and stalk sectors and a transmembrane basepiece, making
up a tripartite structure (MacLennan and Reithmeier,
1985). The enzyme is asymmetrically oriented in the
membrane with virtually all of its extramembranous mass
in the cytoplasm. Thus our first task on obtaining the
deduced amino acid sequence of the protein from analysis
of a cDNA was prediction of the topology and the
secondary structure of the Ca2+-ATPase that would be
consistent with a headpiece, stalk and basepiece structure.
These predictions were carried out in collaboration with
Drs. Michael Green and Willie Taylor. We were guided
by the fact that NH2 and COOH-termini, as well as
tryptic cleavage and ATP binding sites are located in the
cytoplasm and that disulfide bonds in the protein must
exist in the luminal region of the protein. Analysis of
hydrophobic sequences led to assignment of 10 transmem-
brane helices, 4 in the NH2-terminal quarter and 6 in the
COOH-terminal quarter, to make up a basepiece with
very little protrusion into the luminal space (MacLennan
et al., 1985; Brandl et al., 1986). The stalk sector was
proposed to be made up of five predicted alpha helices that
are contiguous with transmembrane helices. We pre-
dicted that the headpiece would be made up of three
globular domains, the first a seven membered beta strand
domain lying between stalk sectors 2 and 3 and the second
and third occurring in alternating alpha-beta sequences
lying between stalk sectors 4 and 5. The second and third
cytoplasmic domains would be rejoined by a long helix at
the COOH-terminal end of the third domain and this
would form a hinge between the two. We have called these
two predicted domains the phosphorylation domain and
the nucleotide binding domain.
Crystallization of the Ca2+-ATPase is currently being
carried out (Taylor et al., 1988; Stokes and Green, 1990)
and analysis of x-ray diffraction patterns will ultimately
solve the structure of the protein. In the meantime, other
approaches provide useful information. In our model of
the Ca2' ATPase (Fig. 1) the sequence between residues
758 and 994 makes up 6 transmembrane helices which
form three hairpin loops in the membrane with residues
783-789, 859-896, and 950-962 lying in the lumen
(Brandl et al., 1986). This folding model has been
suipported by the work of Matthews et al. (1989) who used
monoclonal antibodies to show that the NH2- and COOH-
termini are cytoplasmic. Shull and Greeb (1988) also
showed that the plasma membrane Ca2+ ATPase has six
distinct hydrophobic sequences in this region and that the
calmodulin binding site, which must be cytoplasmic, is
located near the COOH-terminus, following the tenth
proposed transmembrane sequence.
We have used monoclonal antibodies (mAbs) to pro-
vide further evidence for this model (Clarke et al.,
1990d). Antibody A52 (Zubrzycka et al., 1984) reacts
with the sequence 657-672 which we predict to be
cytoplasmic. We have found that A52 binds equally to the
ATPase in sarcoplasmic reticulum preparations in the
presence and absence of the detergent C12E8, confirming
this prediction. A second monoclonal, A20, reacts with
the sequence 870-890. MAb A20 binding to intact
sarcoplasmic reticulum vesicles was virtually at back-
ground level, but was increased 20-fold in the presence of
the detergent, C12E8 or when vesicles were opened by
EGTA at elevated pH. These observations demonstrated
the localization of the sequence 870-890 on the luminal
surface of the sarcoplasmic reticulum and are consistent
with 2, 4, or 6 transmembrane sequences in the COOH
terminal quarter.
Function
The Ca2+-ATPases are members of a class of asymmetri-
cally oriented, transmembrane proteins of 110 kDa
which form a phosphoprotein intermediate during the
course of ATP hydrolysis, which alternate between El and
E2 conformations, and which transport ions either uni- or
bidirectionally. The Ca2+-ATPase of rabbit fast-twitch
muscle sarcoplasmic reticulum binds 2 mol of Ca2+ with
high affinity and 1 mol of ATP per mole of protein (Inesi,
1985). The two Ca2, ions are bound sequentially in two
sites. The first Ca2+ bound is the first to be released to the
lumen in the forward reaction; the second Ca2, bound is
the first to be released to the cytoplasm in the reverse
reaction (Inesi, 1987). As ATP is hydrolyzed, a phos-
phorylated intermediate is formed which is initially of
high energy and capable of carrying out ATP/ADP
exchange (EIP state), but which is transformed to a low
energy conformation (E2P) during the translocation cy-
cle. Ca2 , which is bound initially with high affinity and is
readily exchangeable, is rapidly occluded and no longer
displaceable from the external binding sites by EGTA
(Takisawa and Makinose, 1983). As the reaction cycle
proceeds, the affinity of the Ca2' binding site is reduced
by three orders of magnitude and Ca2+ is released to the
luminal surface as the phosphoprotein decays to a low
energy form. These events can be interpreted as being due
to a change in orientation of helical strands and a
disruption of the Ca2' binding sites formed from them,
resulting in a vectorial transfer of Ca2+ from the cyto-
plasm into the lumen of the sarcoplasmic reticulum
(Tanford, 1982).
The final steps in the process consist of hydrolytic
cleavage of the phosphoenzyme and relaxation of the
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SITE-DIRECTED MUTAGENESIS OF THE SARCOPLASMIC RETICULUM Ca2-ATPASE
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FIGURE 1 Structural diagram of the Ca2+-ATPase molecule based on predicted structure and hydropathy plots. The locations of mutated residues
are circled and the wild type residues are identified by a single letter code. The functional consequence of each mutation is indicated by a color code:
green = no effect on Ca2" transport; yellow = reduced rate of Ca2" transport; red = background level of Ca2" transport; white = no expression of
mutant. Note the clustering of red and yellow mutants near the center of the transmembrane domain, where we predict the sites of Ca2" binding to lie,
and in the loops between alpha helices and beta strands in the cytoplasmic domain, where we believe the site of ATP binding to lie. Mutations in the
stalk sector and in the periphery of the transmembrane domain had little effect on Ca2l transport function.
enzyme from the E2 to the El conformation, with reforma-
tion of the high affinity Ca2+ binding sites. The entire
process is reversible. The enzyme can be phosphorylated
by inorganic phosphate (Pi), provided all Ca2+ is seques-
tered by EGTA (de Meis and Vianna, 1979). The
presence of Ca2+ may drive the E2 form of the enzyme to
the El conformation where it cannot be phosphorylated by
inorganic phosphate. The phosphorylated intermediate
can then be transferred to ADP to form ATP if Ca2+ and
ADP are added simultaneously.
In early models of the Ca2+ ATPase we postulated that
Ca2+ would bind with high affinity in the acidic stalk
sector whereas ATP would bind on the surface of the
headpiece (Brandl et al., 1986; MacLennan et al., 1986).
Rotation of parts of the stalk sector, as a result of ATP
hydrolysis and phosphorylation of the enzyme, would
move Ca2+ into a channel formed by stalk and transmem-
brane sequences, at the same time breaking up the high
affinity Ca2+ binding sites and releasing Ca2+ so that it
could flow into the lumen through a channel formed from
transmembrane sequences. In support of this model,
studies of fluorescence energy transfer among various
sites have indicated that the Ca2' binding sites and the
ATP binding site are widely separated in the molecule
and that the ATP binding site is distant from membrane
lipids (Scott, 1985; Teruel and Gomez-Fernandez, 1986;
Joshi and Shamoo, 1988).
To test our ideas concerning ligand binding sites and
the transport mechanism we decided to use site-directed
mutagenesis to examine structure/function relationships.
This method has provided a novel approach to further
advancement of knowledge in this area.
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SITE SPECIFIC MUTAGENESIS OF THE
Ca2+-ATPASE
Expression and mutagenesis
In our expression-mutagenesis system, developed by Dr.
Kei Maruyama, a postdoctoral fellow in my laboratory
and a former student of Dr. S. Ebashi, full length cDNAs
encoding both slow-twitch and fast-twitch muscle iso-
forms of the Ca2+-ATPase of rabbit muscle sarcoplasmic
reticulum were inserted into the expression vector
p91023(b) and expressed in COS-1 cells (Maruyama and
MacLennan, 1988). Microsomal fractions isolated from
the transfected COS-1 cells transported Ca2+ at rates
-20-50-fold over background, proving that the single
protein encoded by the Ca2+-ATPase cDNA is capable of
carrying out the complete Ca2+ transport function. Immu-
nofluorescence microscopy showed that the expressed
Ca2+-ATPase was localized within organellar structures
in the transfected COS-1 cells whereas Western blotting
and functional analysis showed that the Ca2+ pump is
associated with microsomal fractions from these cells.
Dr. Maruyama, and later Dr. David Clarke (Maruyama
et al., 1989; Clarke et al., 1989a, b and 1990a-c; Vilsen
et al., 1989; Anderson et al., 1989; Fujii et al., 1989)
demonstrated the feasibility of making virtually any
mutation at a rapid rate and carrying out a range of
functional assays on the mutated product. Virtually all of
our mutations lead to products that can be expressed.
Moreover, a large percentage of them have little effect on
function, suggesting that, where perturbation of the
function of the enzyme does occur, it is a meaningful
event. In those mutants where overall activity is lost,
partial reactions usually remain, allowing us to gain
insight into the particular steps in overall Ca2+ transport
that are affected by the mutations. Dr. G. Inesi assisted us
in the early analysis of the phosphorylation of mutant
proteins.
With our expression/mutagenesis system the cells on
five 10-cm plates synthesize -2-3 ,ug of the ATPase
protein. With 2-3 ,ug of ATPase protein we can establish
a Ca2+ transport curve with up to 10 data points. With
another 2-3 ,tg we can carry out studies of phosphoryla-
tion and dephosphorylation or we can measure the Ca2+-
dependency of Ca2+ transport. We can also analyze
electrophoretic mobility changes brought about by pro-
tein modification or proteolysis using PAGE and Western
blotting. We cannot measure Ca2+ or ATP binding or
Ca2+-dependent ATP hydrolysis directly because the
microsomal fraction is crude and the background binding
and nonspecific ATPase levels are high. Moreover, we do
not have sufficient material for extensive kinetic analysis.
Mutational analysis of Ca2+
binding sites
In Fig. 1, we present a summary of our mutations in the
Ca2+-ATPase on the background of our predicted model
for its structure. The function of each mutation is color
coded like a stop light; red means "stop," green means
'go," and yellow means "proceed slowly."
One of our major objectives in site-directed mutagene-
sis of the Ca2+-ATPase was to define the Ca2' binding
sites in the molecule. Because we could find no evidence
for any known high affinity Ca2+ binding sequence in our
initial analysis of the primary structure of the protein, we
proposed that Ca2+ might bind in amphipathic helices of
the stalk sector (Brandl et al., 1986). Accordingly, in our
first study, we mutated a total of 31 Glu, Gln, Asp, and
Asn residues in this sector, usually to Ala, a small
uncharged residue (Clarke et al., 1989a). In most cases,
multiple mutations (clusters of 3-4 altered residues)
introduced into stalk or luminal sectors 1, 2, 3, or 5
resulted in only partial reduction of Ca2+ transport
function whereas subsequent mutation of single residues
in the cluster had no effect on activity. Measurement of
the Ca2+-dependency of Ca2+ transport, an approximate
measurement of Ca2+ binding affinity, showed that none
of these mutations altered Ca2' affinity. Following muta-
tion of one cluster in stalk sector 2, Ca2+ transport was
reduced to near zero. It was possible to assign the
transport defect to alterations in Asn 111 in which Ca2+
transport was lost and Asn 114 in which it was reduced to
50%. Nevertheless, these two mutated proteins were
phosphorylated as effectively as wild type by ATP in the
presence of Ca2+ and no phosphorylation was observed in
the absence of Ca2+. Thus, in these mutants, as in all
mutations in the stalk sector, the Ca2+ binding sites were
intact. We concluded that none of the acidic or amidated
residues in stalk or luminal sectors 1, 2, 3, or 5 are
involved in a critical way in Ca 2+ transport.
In a second series of experiments, we mutated all
charged residues in those sequences of the protein which
we had earlier predicted would lie in the transmembrane
sector of the protein (Clarke et al., 1989b), then all polar
residues (Clarke et al., 1990a) and, finally, three proline
residues (Vilsen et al., 1989) located in this same sector.
In all, 34 amino acid residues in the transmembrane
domain were substituted, some with several alternate
amino acids. Of these substitutions, 20 had no significant
effect on Ca2+ transport, four reduced Ca2+ transport,
and 10 resulted in loss of Ca2+ transport. For those four in
which Ca2+ transport rates were reduced, each caused an
alteration in Ca2+ affinity. We refer to these mutants as
Ca2' affinity mutations.
Of the 10 mutations which caused loss of Ca2, trans-
port, the three Pro and one Lys mutations permitted
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phosphorylation of the protein from ATP in the presence
of Ca2+. Two of the pro mutations had altered affinities
for Ca2+, however. With each of these proline mutants, as
with the Asn 111 to Ala mutant described earlier, the
phosphorylated intermediate was found to be in the high
energy E,P form because each was dephosphorylated by
ADP. When the forward reaction was stopped by seques-
tration of Ca2+ with EGTA, however, the phosphorylated
intermediate was found to be stable. It could not go
forward to form the E2P intermediate and be dephos-
phorylated, but rather appeared to be blocked in the E1P
conformation. We refer to these mutants as conforma-
tional change mutants (Vilsen et al., 1989).
The remaining six mutant proteins, with substitutions
for Glu309, Glu771, Asn796, Thr799, Asp800, and
Gln908 in M4, M5, M6, and M8, which we refer to as Ca2+
binding mutants (Clarke et al., 1989b), were not phos-
phorylated by ATP in the presence of Ca2+, but were
phosphorylated by Pi in the absence of Ca2+. In the wild
type enzyme, Ca2+ inhibits phosphorylation by Pi, appar-
ently by driving the enzyme towards the El conformation.
In these six mutants, Ca2+ did not inhibit phosphorylation
by Pi. This could be due to destruction of the Ca2+
binding site or to inability of the mutants to assume the El
conformation. We believe that the mutations affect the
Ca2+ binding site for two reasons. First, many of the
mutations were isosteric (Glu for Gln or Asp for Asn) and
would have minimal effects on residue size. Second, we
have been able to make alternate substitutions in four of
these sites and have observed that overall Ca2+ transport
function (Ser for Thr799; Gln for Glu980) or partial
reactions (Asp for Glu309; Ala for Asn796) could be
preserved. In all cases, however, preservation of function
occurred with altered affinity for Ca2 . On the basis of our
studies, we have put forth the hypothesis that the Ca2+
binding sites in the Ca2+ ATPase are located near the
center of the transmembrane domain and are comprised
of residues in transmembrane sequences M4, M5, M6,
and M8.
Analysis of ATP binding sites
In a third study (Maruyama et al., 1989), we investigated
the effects of mutation of residues in the phosphorylation
and nucleotide binding domains to elucidate their role in
ATP binding and phosphorylation (see Fig. 1). Muta-
tions were carried out initially in the sequence
ICSDKTGTLT357, which contains the phosphorylated
residue Asp351 and is highly conserved in all P-type
cation pumps. All mutations of Asp351, Lys352, or
Thr353 disrupted Ca2+ transport function and, for Asp35 1
and Lys352, phosphoenzyme formation. Conservative
substitutions in each of the residues flanking Asp35 1,
Lys352, and Thr353, or the alteration of Cys349 to Ala,
did not destroy Ca2+ transport activity or phosphoenzyme
formation. Nonconservative substitutions for any of these
residues, however, did disrupt function.
We have also examined the effect of mutating residues
in several other conserved regions of the ATPase
proposed to be involved in ATP binding (Clarke
et al., 1990c). These are: KGAPE519; DPPR604;
RDACGIRVIMITGDNK629; TGD703; and D707. In
models presented by Taylor and Green (1989) and
Serrano (1989) Lys515, Asp601, Asp627, Asp7O3, and
Asp7O7 were predicted to be involved in ATP binding.
Substitutions for some, but not all, of these residues led to
virtually complete loss of Ca2, transport. We have been
able to show that ATPases with substitution of Glu for
Asp6O1, Glu for Pro6O3, Ala or Pro for Gly626, and Asn
for Asp7O7 did not form detectable phosphoenzyme
intermediates in the presence of either ATP or Pi. These
results are consistent with the involvement of these
residues in ATP binding, but do not prove their involve-
ment. All other substitutions did form phosphoenzyme
intermediates in the presence of 2 uM ATP, indicating
that the ATP binding site was probably intact. Thus
further work is required to obtain a better understanding
of the residues involved in formation of the Ca2' binding
site.
Model for Ca2+ transport
Our studies to date have allowed us to develop a very
simple model for Ca2+ transport as follows: when the
Ca2+ ATPase is in the El conformation, cytoplasmic Ca2+
has free access to two binding sites near the center of the
transmembrane domain where it binds with high affinity.
ATP also has free access to an ATP binding site located in
the headpiece domain. The Ca2+ binding sites and the
ATP binding site are coupled at a distance through
peptide strands in the stalk and headpiece, which form a
syncytium capable of energy transfer between the two
sites. When Ca2+ is bound in Ca2+ binding sites, ATP can
phosphorylate Asp351; when Ca2+ is absent from the
Ca2' binding sites, Pi can phosphorylate Asp351. The
level of energy in the phosphoryl group of Asp351 is
related to the affinity for Ca2+ at the Ca2+ binding sites.
All of these observations support the view that the state of
the ATP binding site influences the state of the Ca2+
binding sites and that energy transferred from ATP to
Asp351 is used to alter the conformation of the Ca2+
binding sites. In the El and E1P conformations, the Ca2+
binding sites are of high affinity. In the transition to the E2
conformation the Ca2+ binding sites are disrupted, lead-
ing to low affinity for Ca2 . In this transition, access of
bound Ca2+ to the cytoplasm is lost, but Ca2+ released
from the disrupted site gains access to the lumen. Thus,
the overall "translocation" of Ca2+ simply involves diffu-
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sional entry of Ca2+ to high affinity binding sites near the
center of the transmembrane domain and diffusional
movement away from disrupted low affinity sites. The
Ca2, translocation site can be compared with a turnstile
in a subway system. Ca2' enters and exits on its own
diffusional energy, but can only pass the barrier through
investment of a "token," in this case, activation of the site
by a distant high energy source, the hydrolysis of ATP.
This model is presented in Fig. 2.
THE CA2+ RELEASE CHANNEL PROTEIN
Structure and function
Each myofibril is segmented into sarcomeric structures
and the sarcoplasmic reticulum surrounding it is also
segmented into longitudinal reticulum with terminal cis-
ternae at either end. The terminal cisternae from adjacent
segments do not abut each other, but are separated by a
transverse tubule, an invagination of the sarcolemma
which carries a depolarizing current into the interior of
the cell. In thin sections it can be seen that the transverse
tubule and the terminal cisternae are connected by a
series of proteinaceous "feet" structures (Franzini Arm-
strong, 1979; Ferguson et al., 1984; Block et al., 1988)
which have recently been identified as the Ca2+ release
channel of the sarcoplasmic reticulum (Fleischer and
Inui, 1989).
Identification and isolation of the Ca2+ release channel
were facilitated through the use of the plant alkaloid,
ryanodine, which was shown to bind to the protein with
HIGH AFFINITY
high affinity and to modulate its function (Fleischer and
Inui, 1989). Single channel recordings showed that puri-
fied "ryanodine receptor" preparations, comprised of
homotetrameric complexes of a single polypeptide of
565,000, exhibit an intrinsic Ca2+ channel activity that is
modulated by Ca2+, ATP, and Mg2+ in a manner similar
to native Ca2' release channels (Imagawa et al., 1987;
Hymel et al., 1988; Smith et al., 1988; Lai et al., 1988).
Studies of the morphology of the ryanodine receptor
(Wagenknecht et al., 1989) have shown it to have a
quatrefoil structure, with hydrophobic segments of the
four identical subunits forming a putative membrane-
spanning baseplate structure, and hydrophilic segments
forming a cytoplasmic domain that surrounds and deco-
rates the central baseplate. Three-dimensional image
reconstruction suggests the presence of four internal
channels which branch from a common origin above the
baseplate and open into vestibules in the four quarters of
the tetramer.
Drs. Francesco Zorzato, Junichi Fujii, and Kinya Otsu,
postdoctoral fellows in my laboratory have cloned cDNAs
encoding both skeletal and cardiac forms of the Ca2+
release channel (Zorzato et al., 1990; Otsu et al., 1990).
The two proteins are essentially colinear, although there
are many gaps or additions over the 5,000 or so amino
acid residues making up their sequences. As is usual in
protein isoforms, hydropathy plots, repeat sequences,
predicted secondary structure, and predicted ligand bind-
ing sites are well conserved between the two proteins.
Although very little hard evidence is yet available concern-
ing structural features of the protein, predictions of its
LOW AFFINITY
Discharge
FIGURE 2 Model illustrating the mechanism of Ca2" transport by the Ca2+-ATPase. In the El conformation, high affinity Ca2' binding sites located
near the center of the transmembrane domain are accessible to cytoplasmic Ca2+, but not to luminal Ca2, (high affinity state). The sites are made up
from amino acid residues located in proposed transmembrane sequences M4, M5, M6, and M8. Conformational changes induced by ATP hydrolysis
lead to the E2 conformation in which the high affinity Ca2' binding sites are disrupted, access to the sites by cytoplasmic Ca2, is closed offand access to
the sites by luminal Ca2, is gained (low affinity state). The Ca2, transport cycle thus involves binding of cytoplasmic Ca2, to high affinity sites in one
conformation and release of the same Ca2, to the lumen when the high affinity sites are disrupted in the transition to the second conformation.
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FIGURE 3 Structural diagram of the Ca2" release channel of the
sarcoplasmic reticulum (ryanodine receptor) based on predicted struc-
ture and hydrophathy plot. The morphology of the ryanodine receptor
suggests that much of its cytoplasmic bulk lies in the gap between the
sarcoplasmic reticulum and the transverse tubule, that this bulk is made
up from a homotetramer and that radial channels lie within the
structure (Wagenknecht et al., 1989). The ryanodine receptor appears
to abut dihydropyridine receptors (slow Ca2" channels) in the transverse
tubule and may be functionally coupled to them (Block et al., 1988). The
transmembrane domain is made up of 4 to 12 transmembrane se-
quences, 4 to 10 of which are in the COOH-terminal fifth of the
molecule and 2 of which are more central. The postulated modulator
binding domain is proposed to lie between amino acid residues 2,600 and
3,000, on an exposed surface of the cytoplasmic domain near cytoplas-
mic channel openings.
structure can be made. The hydropathy plots show four
very hydrophobic sequences near the COOH-terminus of
the protein (Fig. 3). Takeshima et al. (1989) suggested
that these were the only transmembrane sequences in the
protein. We identified eight additional sequences which
are potential transmembrane sequences. In our analysis,
10 of these would reside in the COOH-terminal end of the
molecule and two more would reside in a more central
location. The remainder of the protein, -95% of its mass,
would make up the foot structure spanning the gap
between the sarcoplasmic reticulum and the transverse
tubule. We predicted that very little mass would lie in the
lumen of the sarcoplasmic reticulum. We noted four
repeat sequences, -120 amino acids in length, in the
NH2-terminal sector of the protein, but we do not yet
know how these relate to function. Finally, we noted a
region between amino acid residues 2600 and 3000 that is
surface exposed and very hydrophilic and which contains
predicted ATP and calmodulin binding sites as well as a
potential phosphorylation site in the cardiac isoform
(Otsu et al., 1990). We believe that this represents a
modulator binding region in the protein (Fig. 3).
Cloning of cDNA encoding the Ca2' release channel
protein has opened up new avenues of investigation of the
protein, including its primary and predicted secondary
structure, its expression and mutagenesis and its genomic
structure, localization, and involvement in disease. Our
cloning of cDNA encoding the human skeletal muscle
ryanodine receptor allowed us to localize the ryanodine
receptor (RYR1) gene to human chromosome 19ql3.1
(Mackenzie et al., 1990). We have isolated most of the
genomic DNA encoding the normal human ryanodine
receptor and used cDNA probes to identify exon-
containing sequences. We have sequenced genomic DNA
containing -90% of the exon sequences and their flanking
intron sequences. Although we have not yet analyzed the
entire sequence, we believe that the gene is between
200,000 and 300,000 bp long and will ultimately contain
-100 exons (M. Phillips, J. Fujii, and D. H. MacLennan,
unpublished studies). A major objective in analyzing
human RYRI DNA was to determine whether the RYRI
gene is involved in human genetic disease, in particular
malignant hyperthermia.
MALIGNANT HYPERTHERMIA
Manifestation
Malignant hyperthermia (MH) is manifested in humans
and swine as an acute hyperthermic reaction, usually
accompanied by skeletal muscle contracture, which is
triggered by potent inhalation anaesthetics and muscle
relaxants (Britt, 1985; O'Brien et al., 1990). Fever is a
result of hypermetabolism in the muscle and not a cause
of the biochemical abnormalities that occur in skeletal
muscle in an MH reaction. As a result, it occurs late in
onset but it may rise at a rapid rate, reaching 44-460 in a
short period. Reactions can also be induced, rarely in
humans but commonly in swine, by environmental stresses
such as high temperature, infection, emotional excite-
ment, muscle injury, or exercise. In the absence of
triggering agents, susceptible individuals appear normal.
Susceptibility to the disease is inherited in humans as an
autosomal dominant trait, but in swine it is an autosomal
recessive trait. The incidence of MH reactions is 1 in
15,000 anaesthesias in children's hospitals and 1 in
50,000 to 1 in 150,000 anaesthetics in adult hospitals.
Physiological, biochemical, and
genetic basis for MH
The aetiology of MH is fully consistent with a lack of
regulation of Ca2+ within muscle cells, either through an
enhanced or chronic release of Ca2+ into the cell or
through defective reuptake of Ca2+. The continued pres-
ence of Ca2+ within muscle cells would account for
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muscle contracture, whereas the continued hydrolysis of
ATP would account for elevated temperature and for
excess 02 uptake and CO2 release due to metabolic
regeneration of ATP. Although the resting level of Ca2,
in MH susceptible swine was not found to be different
using the dye Fura 2 as an indicator, intracellular Ca2+
was dramatically raised in these intact fibers by the
infusion of caffeine or halothane (Iaizzo et al., 1988).
Thus, the abnormal tension induced by caffeine and
halothane in MH muscle is correlated with abnormal
release of Ca2, into the myoplasm.
Studies carried out on the response of sarcoplasmic
reticulum isolated from MH susceptible (MHS) and MH
normal (MHN) pigs to halothane and caffeine confirm
that Ca2+ reuptake through the Ca2+ pump is not
involved in MH (Nelson et al., 1986) but that the rate and
extent of Ca2' release from MHS sarcoplasmic reticulum
exceeds the rate of Ca2+ release from MHN sarcoplasmic
reticulum. Moreover, the threshold of activation of Ca2,
release by such agents as caffeine, halothane, and even
Ca2, itself, is lowered in MHS sarcoplasmic reticulum
(Endo et al., 1983; O'Brien et al., 1990).
Such studies implicate defects in the Ca2' release
channel as causative of MH. In analysis of potential
defects, Mickelson et al. (1988) have shown that the
MHS ryanodine receptor exhibits an altered Ca2' depen-
dence of [3H] ryanodine binding at the low affinity Ca2,
site, as well as a lower Kd for ryanodine, when compared
with that from MHN pigs. Knudson et al. (1990) found
that the tryptic digestion pattern of the ryanodine recep-
tor differed between MHN and MHS pigs. These abnor-
malities of the channel may reflect an intrinsic defect in
the MHS ryanodine receptor leading to malignant hyper-
thermia.
Genetic analysis of the inheritance of the halothane
sensitive (HAL) gene in pigs, using a halothane challenge
for diagnosis, has led to its assignment to a linkage group
on pig chromosome 6 (Davies et al., 1988). Because the
same linkage group is localized on the same region of the
long arm of human chromosome 19 where we found the
RYR I gene, analysis of the linkage of the RYRI and MH
genes became a high priority in our studies.
Linkage between RYRI and
MH genes
After we had obtained the first human cDNA clones and,
in collaboration with Drs. H. F. Willard, R. G. Korneluk,
and B. Wieringa, localized the gene to human chromo-
some 19q 13.1, we initiated a collaboration with Drs. R. G.
Worton and B. A. Britt to carry out linkage analysis
between the MH gene and the RYRI gene in affected
families (MacLennan et al., 1990). Catherine Duff in Dr.
Worton's group was able to detect several useful restric-
tion fragment length polymorphisms (RFLPs) in the
human RYR1 gene which formed the basis for our
linkage study between the MH and RYRI genes.
Dr. Britt has carried out diagnosis of patients in MH
families over the course of the past 19 years using the
halothane and caffeine contracture test that she and Dr.
Kalow originally developed in Toronto (Kalow et al.,
1970). Thus several family trees were available for study
of the cosegregation of the MH gene and the RFLPs in
the RYRI gene. Nine families were found in which at
least one RFLP was informative. In each family, the
affected parent was heterozygous for the RYRI polymor-
phism, whereas the unaffected parent was homozygous
for the marker, making all of the children informative. In
each of the nine families, there was cosegregation of a
single RYRI allele with the MH phenotype and, in a
study of 23 meioses, no recombination was found between
the MH gene and the RYRI gene. The log of the odds
(lod score) that the MH and RYRI genes are linked, is
4.2 with a theta max of 0.0 (MacLennan et al., 1990).
Flanking markers also displayed tight linkage, although,
as anticipated, recombination occurred with some mark-
ers. Linkage does not prove that the two genes are the
same, but only demonstrates that they lie within a
common region of -1 million base pairs. Nevertheless,
there is strong justification, from both physiological and
genetic studies, for the view that the RYRI gene and the
MH gene are one and the same. Current studies in our
laboratory are designed to discover whether mutant
sequences, leading to MH, exist in both human and pig
ryanodine receptor genes.
CONCLUSION
Our studies of the sarcoplasmic reticulum were begun
with the hope of understanding the mechanism of Ca2+
transport and release. They have extended from protein
chemistry through molecular cloning to expression, mu-
tagenesis, and human genetics. They provide an example
of the way that utilization of new technologies, as they
develop, can provide new solutions to old problems,
thereby bringing us ever closer to full understanding of
complex biological mechanisms. In restrospect, it was
always more fun to learn and apply new technologies to
old problems than to struggle with the old technology or to
discard the old problems.
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